Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Subacute sclerosing panencephalitis Indication Strategy Report 2026: Measles polymerase, Trials and Deals
3 August 2026
2026 Subacute sclerosing panencephalitis indication strategy covering epidemiology, Measles polymerase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Fusariosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Fusariosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Congenital rubella syndrome Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Congenital rubella syndrome indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Scedosporiosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Scedosporiosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Mycetoma Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Mycetoma indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Dracunculiasis Indication Strategy Report 2026: Glutamate-gated chloride channel, Trials and Deals
3 August 2026
2026 Dracunculiasis indication strategy covering epidemiology, Glutamate-gated chloride channel biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Chromoblastomycosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Chromoblastomycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Loiasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
3 August 2026
2026 Loiasis indication strategy covering epidemiology, Wolbachia biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Congenital toxoplasmosis Indication Strategy Report 2026: DHFR, Trials and Deals
3 August 2026
2026 Congenital toxoplasmosis indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Visceral larva migrans Indication Strategy Report 2026: Beta-tubulin, Trials and Deals
3 August 2026
2026 Visceral larva migrans indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Granulomatous amebic encephalitis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Granulomatous amebic encephalitis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Naegleria fowleri infection Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Naegleria fowleri infection indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market…